Boobalan Pachaiyappan
Stock Analyst at Roth Capital
(3.90)
# 635
Out of 4,920 analysts
16
Total ratings
50%
Success rate
13.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAPR Capricor Therapeutics | Maintains: Buy | $31 → $12 | $7.67 | +56.56% | 2 | Jul 14, 2025 | |
| VRNA Verona Pharma | Reiterates: Buy | $92 → $116 | $105.35 | +10.11% | 2 | Jun 18, 2025 | |
| PYPD PolyPid | Maintains: Buy | $12 → $9 | $3.39 | +165.49% | 2 | Jun 18, 2025 | |
| CING Cingulate | Maintains: Buy | $12 → $11 | $5.48 | +100.73% | 2 | May 19, 2025 | |
| CRVO CervoMed | Maintains: Buy | $15 → $20 | $9.77 | +104.71% | 3 | Mar 18, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Initiates: Buy | $7 | $0.45 | +1,447.65% | 1 | Jan 10, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 | $1.49 | +369.80% | 2 | Dec 24, 2024 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $5.94 | +388.22% | 1 | Dec 5, 2024 | |
| LGVN Longeveron | Initiates: Buy | $10 | $1.58 | +532.99% | 1 | Dec 5, 2024 |
Capricor Therapeutics
Jul 14, 2025
Maintains: Buy
Price Target: $31 → $12
Current: $7.67
Upside: +56.56%
Verona Pharma
Jun 18, 2025
Reiterates: Buy
Price Target: $92 → $116
Current: $105.35
Upside: +10.11%
PolyPid
Jun 18, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $3.39
Upside: +165.49%
Cingulate
May 19, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $5.48
Upside: +100.73%
CervoMed
Mar 18, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $9.77
Upside: +104.71%
Reviva Pharmaceuticals Holdings
Jan 10, 2025
Initiates: Buy
Price Target: $7
Current: $0.45
Upside: +1,447.65%
Gain Therapeutics
Dec 24, 2024
Maintains: Buy
Price Target: $7
Current: $1.49
Upside: +369.80%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $5.94
Upside: +388.22%
Longeveron
Dec 5, 2024
Initiates: Buy
Price Target: $10
Current: $1.58
Upside: +532.99%